3.06
                                            Editas Medicine Inc Stock (EDIT) Forecast
The Editas Medicine Inc (EDIT) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $16.39, representing a +435.63% increase from the current price of $3.06. The highest analyst price target is $20.46, and the lowest is $12.32.
                Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
        12-Month EDIT Price Target
            
                Average 49.16 
                (+1,506% Upside)
                
                    
                        
                    
                
            
        Is Editas Medicine Inc (EDIT) A Buy Now?
Oscillators
                | Name | Value | Action | 
|---|---|---|
| RSI(14) | 41.35 | Neutral | 
| STOCH(9,6) | 8.2415 | Buy | 
| STOCHRSI(14) | 5.8101 | Buy | 
| MACD(12,26) | -0.0786 | Sell | 
| ADX(14) | 20.95 | Neutral | 
| William %R | -86.99 | Buy | 
| CCI(14) | -107.98 | Sell | 
                            Buy: 3
                            Sell: 2
                            Neutral: 2
                        
                        Summary: Buy
                        Moving Averages
                | Period | Simple | Exponential | 
|---|---|---|
| MA10 | 
                                     3.343 
                                        Sell 
                                     | 
                                
                                     3.2893 
                                        Sell 
                                     | 
                            
| MA20 | 
                                     3.6195 
                                        Sell 
                                     | 
                                
                                     3.414 
                                        Sell 
                                     | 
                            
| MA50 | 
                                     3.2308 
                                        Sell 
                                     | 
                                
                                     3.2713 
                                        Sell 
                                     | 
                            
| MA100 | 
                                     2.9234 
                                        Buy 
                                     | 
                                
                                     2.948 
                                        Buy 
                                     | 
                            
| MA200 | 
                                     2.2149 
                                        Buy 
                                     | 
                                
                                     2.7971 
                                        Buy 
                                     | 
                            
                            Buy: 4
                            Sell: 6
                            Neutral: 0
                        
                        Summary: Sell
                        
                According to our latest analysis, EDIT could be considered a Moderate Sell, with 17 technical analysis indicators signaling 7 Buy signals, 8 signaling Sell signals and 2 Neutral signals. This might not be a good time to consider opening new positions on EDIT, as trading bearish markets can be challenging and may result in losses.
            
            - RSI (Relative Strength Index): The RSI(14) value of 41.35 indicates that EDIT is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
 - STOCH (Stochastic Oscillator): The STOCH value of 8.2415 indicates that EDIT is oversold. This indicates that EDIT price is at or near the lowest level over a specified lookback period.
 - STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 5.8101 indicates that EDIT is oversold. This suggests that EDIT price is at or near the lowest level relative to its recent price history.
 - ADX (Average Directional Index): The ADX value of The ADX value of 20.95 suggests that there may be some movement in price, but it lacks strength or conviction.
 - CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -107.98 indicates that EDIT is oversold. This means that the price has moved significantly lower than its average, indicating a potential buying opportunity.
 
Long-term EDIT price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Editas Medicine Inc financial reports and earnings history, Editas Medicine Inc (EDIT) stock could reach $15.36 by 2030, $15.11 by 2040 and $36.12 by 2050. See the projected annual prices until 2050 of the Editas Medicine Inc stock below:
- Editas Medicine Inc (EDIT) is expected to reach an average price of $0.6512 in 2035, with a high prediction of $4.796 and a low estimate of $1.4212. This indicates an $-78.72% rise from the last recorded price of $3.06.
 - Editas Medicine Inc (EDIT) stock is projected to chart a bullish course in 2040, with an average price target of $13.72, representing an $348.35% surge from its current level. The forecast ranges from a conservative $14.23 to a sky-high $15.11.
 - Our analysts predict Editas Medicine Inc (EDIT) to jump 674.04% by 2045, soaring from $22.09 to an average price of $23.69, potentially reaching $22.74. While $22.09 is the low estimate, the potential upside is significant.
 - Editas Medicine Inc (EDIT) stock is expected to climb by 2050, reaching an average of $34.39, a $1,024% jump from its current level. However, a wide range of estimates exists, with high and low targets of $36.12 and $36.98, respectively, highlighting the market's uncertainty.
 
Editas Medicine Inc Stock (EDIT) Year by Year Forecast
Editas Medicine Inc Stock (EDIT) Price Forecast for 2025
                                Editas Medicine Inc Stock (EDIT) is expected to reach an average price of $12.58 in 2025, with a high prediction of $24.77 and a low estimate of $0.3883. This indicates an +311.12% rise from the last recorded price of $3.06.
                            
                    | Month | Average | Low | High | Change from today's price | 
|---|---|---|---|---|
| December, 2025 | $16.44 | $12.32 | $20.46 | +437.36% | 
Editas Medicine Inc Stock (EDIT) Price Forecast for 2026
                            The predicted value for Editas Medicine Inc (EDIT) in 2026 is set at an average of $49.33. Estimates vary from a peak of $86.00 to a trough of $12.67, indicating an +1,512% surge from the present price of $3.06.
                        
                    | Month | Average | Low | High | Change from today's price | 
|---|---|---|---|---|
| January, 2026 | $17.04 | $12.67 | $18.48 | +456.88% | 
| February, 2026 | $50.30 | $15.59 | $53.58 | +1,544% | 
| March, 2026 | $62.24 | $48.27 | $86.00 | +1,934% | 
| April, 2026 | $42.83 | $39.09 | $63.04 | +1,300% | 
| May, 2026 | $31.54 | $22.54 | $42.64 | +930.70% | 
| June, 2026 | $26.20 | $23.78 | $35.76 | +756.10% | 
| July, 2026 | $20.20 | $16.33 | $30.22 | +560.24% | 
| August, 2026 | $24.60 | $18.88 | $25.77 | +703.95% | 
| September, 2026 | $36.00 | $20.38 | $47.38 | +1,076% | 
| October, 2026 | $43.11 | $25.21 | $44.50 | +1,309% | 
| November, 2026 | $51.41 | $44.25 | $56.13 | +1,580% | 
| December, 2026 | $29.12 | $27.68 | $60.90 | +851.60% | 
Editas Medicine Inc Stock (EDIT) Price Forecast for 2027
                                For 2027, Stockscan's Analyst expects the average price target for Editas Medicine Inc (EDIT) is $15.29, with a high forecast of $30.52 and a low forecast of $0.0638. This indicates an +399.80% increase from the last price of $3.06.
                            
                    | Month | Average | Low | High | Change from today's price | 
|---|---|---|---|---|
| January, 2027 | $26.00 | $22.55 | $29.24 | +749.55% | 
| February, 2027 | $23.81 | $23.52 | $30.52 | +678.22% | 
| March, 2027 | $18.59 | $15.53 | $24.05 | +507.53% | 
| April, 2027 | $11.01 | $9.8077 | $19.64 | +259.73% | 
| May, 2027 | $7.835 | $5.3763 | $10.65 | +156.05% | 
| June, 2027 | $5.4117 | $2.503 | $9.0844 | +76.85% | 
| July, 2027 | $8.5691 | $3.3204 | $10.14 | +180.04% | 
| August, 2027 | $4.3364 | $4.0064 | $11.24 | +41.71% | 
| September, 2027 | $1.6731 | $0.0638 | $5.7851 | -45.32% | 
| October, 2027 | $1.4805 | $0.2195 | $3.5212 | -51.62% | 
| November, 2027 | $5.3879 | $1.1698 | $5.8179 | +76.07% | 
| December, 2027 | $9.4046 | $3.5472 | $10.60 | +207.34% | 
Editas Medicine Inc Stock (EDIT) Price Forecast for 2028
                                In 2028, Editas Medicine Inc (EDIT) is projected to reach an average price of $4.7939, with a high projection of $9.5639 and a low estimate of $0.0238. This indicates an +56.66% rise from the last price of $3.06.
                            
                    | Month | Average | Low | High | Change from today's price | 
|---|---|---|---|---|
| January, 2028 | $5.6619 | $4.9319 | $9.5639 | +85.03% | 
| February, 2028 | $3.2693 | $3.0793 | $7.2713 | +6.84% | 
| March, 2028 | $3.826 | $2.2466 | $4.3773 | +25.03% | 
| April, 2028 | $1.5033 | $1.034 | $5.5553 | -50.87% | 
| May, 2028 | $0.56 | $0.41 | $2.252 | -81.70% | 
| June, 2028 | $0.0326 | $0.0238 | $1.0687 | -98.93% | 
| July, 2028 | $1.8747 | $0.1733 | $3.9929 | -38.73% | 
| August, 2028 | $0.1914 | $0.1586 | $2.5341 | -93.74% | 
| September, 2028 | $0.5212 | $0.0308 | $1.1458 | -82.97% | 
| October, 2028 | $2.5262 | $0.2125 | $3.2762 | -17.45% | 
| November, 2028 | $2.6729 | $1.7335 | $3.5155 | -12.65% | 
| December, 2028 | $1.4302 | $0.8609 | $5.0115 | -53.26% | 
Editas Medicine Inc Stock (EDIT) Price Forecast for 2029
                                The 2029 price forecast for Editas Medicine Inc Stock (EDIT) is $5.8538 on average, with a high prediction of $11.49 and a low estimate of $0.2176. This represents an +91.30% increase from the previous price of $3.06.
                            
                    | Month | Average | Low | High | Change from today's price | 
|---|---|---|---|---|
| January, 2029 | $2.2269 | $1.2496 | $2.4889 | -27.22% | 
| February, 2029 | $2.4143 | $1.7956 | $3.0163 | -21.10% | 
| March, 2029 | $2.2316 | $2.1316 | $3.2816 | -27.07% | 
| April, 2029 | $1.089 | $0.7753 | $2.5203 | -64.41% | 
| May, 2029 | $1.9557 | $0.2176 | $3.3457 | -36.09% | 
| June, 2029 | $5.2531 | $1.485 | $5.6437 | +71.67% | 
| July, 2029 | $4.8104 | $4.2825 | $6.2224 | +57.20% | 
| August, 2029 | $1.9571 | $1.8771 | $5.0898 | -36.04% | 
| September, 2029 | $2.9345 | $1.8565 | $3.5551 | -4.10% | 
| October, 2029 | $2.8412 | $2.8112 | $6.7538 | -7.15% | 
| November, 2029 | $1.0585 | $0.8535 | $3.0155 | -65.41% | 
| December, 2029 | $13.27 | $0.7279 | $11.49 | +333.66% | 
Editas Medicine Inc Stock (EDIT) Price Forecast for 2030
                                Editas Medicine Inc Stock (EDIT) is expected to reach an average price of $9.3434 in 2030, with a high forecast of $15.36 and a low forecast of $3.3228. This signifies an +205.34% surge from the last price of $3.06.
                            
                    | Month | Average | Low | High | Change from today's price | 
|---|---|---|---|---|
| January, 2030 | $15.11 | $15.52 | $15.36 | +393.68% | 
| February, 2030 | $11.71 | $13.03 | $13.33 | +282.74% | 
| March, 2030 | $11.20 | $11.41 | $10.92 | +265.87% | 
| April, 2030 | $11.16 | $11.83 | $10.87 | +264.79% | 
| May, 2030 | $12.58 | $10.72 | $12.31 | +311.08% | 
| June, 2030 | $13.94 | $13.96 | $14.27 | +355.57% | 
| July, 2030 | $10.18 | $11.91 | $13.01 | +232.71% | 
| August, 2030 | $2.1662 | $3.8912 | $3.7623 | -29.21% | 
| September, 2030 | $2.8515 | $3.5775 | $3.8702 | -6.81% | 
| October, 2030 | $6.2881 | $3.3228 | $4.9381 | +105.49% | 
| November, 2030 | $14.41 | $8.3894 | $9.9634 | +371.03% | 
| December, 2030 | $12.99 | $13.22 | $11.88 | +324.47% | 
        Open in Yahoo
        |
        Open in Google
            |
            Open in Finviz
        |
        Open in MarketWatch
            |
            Open in EDGAR    
        |
        Open in Reuters
    
    
                Cap:
                 
                  | 
                Volume (24h):